Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 6/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.39 |
| ▸ | CYSLTR2 | Q9NS75 | 1/20 | 0.38 |
| ▸ | CYSLTR1 | Q9Y271 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6473587 | 0.93 | TP53 (0.45) | PPARATP53PPARGPOLBMAPT | |
| SCHEMBL6474127 | 0.90 | CYSLTR2 (0.43) | PPARATP53CYSLTR2CYSLTR1MAPT | |
| SCHEMBL6474743 | 0.89 | TP53 (0.44) | TP53MAPTSMN1; SMN2LMNAKDM4E | |
| SCHEMBL6482379 | 0.89 | CTPS1 (0.43) | PPARATP53PPARGCYSLTR2CYSLTR1 | |
| SCHEMBL6483737 | 0.88 | SHMT2 (0.46) | PPARATP53PPARGCYSLTR2CYSLTR1 | |
| SCHEMBL6475724 | 0.85 | TP53 (0.42) | PPARATP53CYSLTR2CYSLTR1POLB | |
| SCHEMBL6474643 | 0.85 | CYSLTR2 (0.39) | PPARATP53PPARGCYSLTR2CYSLTR1 | |
| SCHEMBL6475351 | 0.84 | IKBKB (0.46) | PPARAPPARGIKBKBCYSLTR2CYSLTR1 | |
| SCHEMBL6474761 | 0.83 | CYSLTR2 (0.39) | PPARATP53PPARGCYSLTR2CYSLTR1 | |
| SCHEMBL6474952 | 0.83 | PPARG (0.41) | TP53PPARGCYSLTR2CYSLTR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6930131-B2 | Aryl substituted 3-ethoxy phenyl trifluoromethane sulfonamides for the treatment of non-insulin dependent diabetes mellitus (NIDDM) | WYETH (US) | 2005-08-16 | — | — | US | disclosed |
| US-20030203941-A1 | Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus | WYETH (US) | 2003-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203941-A1 | Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus | GPR119, INSR, SLC5A1 | PPARA 291/4885TP53 3797/4885PPARG 256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.